- Report
- November 2024
- 50 Pages
Global
From €2618EUR$2,650USD£2,179GBP
- Report
- October 2024
Global
From €3458EUR$3,500USD£2,878GBP
- Report
- August 2024
- 69 Pages
China
From €1779EUR$1,800USD£1,480GBP
- Report
- August 2024
- 244 Pages
China
From €3952EUR$4,000USD£3,290GBP
- Report
- March 2024
- 132 Pages
Global
From €939EUR$950USD£781GBP
- Report
- July 2022
- 132 Pages
Global
From €840EUR$850USD£699GBP
- Report
- July 2024
- 280 Pages
Global
From €2623EUR$2,655USD£2,183GBP
- Report
- January 2022
- 216 Pages
Global
From €3668EUR$3,712USD£3,053GBP
- Book
- December 2011
- 200 Pages
The Prostate Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it can vary depending on the stage and severity of the disease. Common treatments include hormone therapy, chemotherapy, and radiation therapy.
The Prostate Cancer Drugs market is highly competitive, with many companies vying for market share. Major players in the market include Astellas Pharma, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are constantly researching and developing new drugs to treat prostate cancer, as well as improving existing treatments. Show Less Read more
